Co-Diagnostics, Inc. has taken a significant step in its financial strategy by filing a registration statement with the Securities and Exchange Commission (SEC) to offer up to 39.6 million shares of its common stock. This move is aimed at enhancing the company's liquidity and financial flexibility, which could be crucial for its future growth and operational needs.

The filing, dated November 4, 2026, indicates that the shares will be offered by J.J. Astor & Co., a Utah corporation, which has also entered into a loan agreement with Co-Diagnostics. This agreement allows for loans totaling up to $3.1 million, with an initial funding of $2.1 million already provided to the company. The loan agreement includes the issuance of a senior secured convertible installment promissory note, which further ties the financing to the company’s stock performance.

Background

Co-Diagnostics, Inc. is a company operating in the surgical and medical instruments and apparatus sector, classified under SIC 3841. The company trades on the Nasdaq under the ticker symbol CODX. As a smaller reporting company, Co-Diagnostics has been navigating the complexities of the medical technology landscape, focusing on innovative diagnostic solutions.

What the Filing Says

The SEC filing states, “The Shares represent 200% of the sum of the maximum number of shares issuable upon conversion of the Notes, the Commitment Shares and any applicable make-whole shares.” This indicates that the company is preparing for a significant number of shares to become available, which could impact its stock performance and investor interest.

Impact

This move may affect various stakeholders, including current and potential investors, as well as competitors in the surgical and medical instruments industry. The influx of new shares could dilute existing ownership but also provide the necessary capital for Co-Diagnostics to pursue growth opportunities. The loan agreement with Astor may also set a precedent for other companies in the industry seeking similar funding arrangements.

What's Next

The filing does not specify what happens next, but it is clear that the company is preparing to engage with the market for its shares. Investors will be watching closely to see how this registration impacts Co-Diagnostics' stock performance and overall market strategy.